Lv1
28 积分 2023-11-13 加入
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
28天前
已完结
抗肿瘤药物申报联合用药 早期临床试验的考虑
29天前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
1个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
1个月前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1个月前
已完结
Advances in targeted therapy for gastric cancer based on tumor driver genes
1个月前
已完结
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study
1个月前
已完结
Forget lung, breast or prostate cancer: why tumour naming needs to change
2个月前
已完结
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
2个月前
已完结
Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
2个月前
已完结
皖公网安备34019202002308
